Evidence map›Paper›PMID 41836418›Full record

ArticleFrontiers in immunology2026

Decoding the role of macrophage LAP3 in lung cancer - integration of single-cell technologies and machine learning reveals an orchestrating immunometabolic circuit at the tumor-epithelial interface.

Yunlong Dong, Xibin Fei, Mengmeng Jiang, Hongsheng Guo, Wencheng Zhang, Xu Chang, Xuanguang Li, Hongjie Zhao, Guangshun Wang

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yunlong Dong *Department of Thoracic Surgery, Tianjin Baodi Hospital, Baodi Hospital Affiliated to Tianjin Medical University, Tianjin, China.
Xibin Fei *Department of Thoracic Surgery, Tianjin Baodi Hospital, Baodi Hospital Affiliated to Tianjin Medical University, Tianjin, China.
Mengmeng Jiang *Department of Medical Oncology, Central Hospital, Tianjin University/Third Central Hospital, Tianjin, China.
Hongsheng GuoDepartment of Medical Oncology, Central Hospital, Tianjin University/Third Central Hospital, Tianjin, China.
Wencheng ZhangDepartment of Thoracic Surgery, Tianjin Baodi Hospital, Baodi Hospital Affiliated to Tianjin Medical University, Tianjin, China.
Xu ChangDepartment of Interventional Therapy II, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Xuanguang LiDepartment of Lung Cancer Surgery, Tianjin Medical University General Hospital, Tianjin, China.
Hongjie ZhaoDepartment of Thoracic Surgery, Tianjin Baodi Hospital, Baodi Hospital Affiliated to Tianjin Medical University, Tianjin, China.
Guangshun WangDepartment of Thoracic Surgery, Tianjin Baodi Hospital, Baodi Hospital Affiliated to Tianjin Medical University, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Amino acid metabolism plays a crucial role in shaping tumor-immune crosstalk in non-small cell lung cancer (NSCLC). However, the key cellular mediators that translate metabolic states into intercellular signals remain poorly defined. Methods: We integrated single-cell RNA-seq with spatial transcriptomics to map immunometabolic architecture. Transcriptional co-variation was decomposed into amino-acid metabolic programs using Non-negative Matrix Factorization (NMF); spatial deconvolution localized programs and cell types in tissue. Myeloid populations were subclustered to resolve macrophage states. Functional assays tested LAP3 overexpression (OE-LAP3) in A549/PC9 cells (qRT-PCR, Western blot, CCK-8, colony formation, wound-healing, Transwell) and a nude-mouse subcutaneous mouse model. Results: Integrative single-cell and spatial transcriptomic analyses revealed that tumor epithelial and myeloid cells dominate the NSCLC microenvironment and exhibit lineage-specific activation of amino acid metabolic programs. Notably, LAP3 was selectively enriched in both tumor epithelium and a distinct macrophage subset. Spatial mapping localized this LAP3-high macrophage state to epithelial-myeloid interfaces, where it functions as a signaling hub, actively secreting chemokines, cytokines, adhesion molecules, and extracellular matrix (ECM) components. To test whether LAP3 plays a causal role in tumor behavior, we established stable LAP3-overexpressing A549 and PC9 cell lines, confirming robust upregulation at both mRNA and protein levels. Functionally, LAP3 overexpression significantly suppressed proliferation-evident in CCK-8 time-course and colony formation assays-and impaired motility and invasiveness, as shown by delayed wound healing and reduced cell migration/invasion in Transwell assays. Most importantly, these effects translated Conclusions: LAP3 appears to functionally link amino acid catabolism to immune communication in NSCLC, defining an epithelial-macrophage immunometabolic niche where metabolic activity may shape the immune contexture. Its overexpression is associated with attenuated malignant phenotypes and heightened immune engagement, suggesting a potential dual role in restraining tumor aggressiveness and fostering an immune-responsive microenvironment. While these findings support LAP3 as a candidate biomarker for patient stratification and provide a rationale for combining metabolic modulation with immunotherapy, further mechanistic and clinical validation remains necessary.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMachine LearningMacrophagesAmino AcidsAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMetabolic ReprogrammingMiceMice, NudeSingle-Cell AnalysisTumor MicroenvironmentAmino Acidsamino-acid metabolismcancer immuneimmunometabolismLAP3ligand–receptormacrophageNSCLCsingle-cell

Identifiers

PMID41836418
PMCPMC12982070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.